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ABSTRACT 
Aim: Contemporary global real-world data on the management of type 2 diabetes are scarce. 
The global DISCOVER study program aims to describe the disease management patterns and 
a broad range of associated outcomes in patients with type 2 diabetes initiating a second-line 
glucose-lowering therapy in routine clinical practice. 
Methods: The DISCOVER program comprises two longitudinal observational studies 
involving more than 15 000 patients in 38 countries across six continents. Study sites have 
been selected to be representative of type 2 diabetes management in each country. Data will 
be collected at baseline (initiation of second-line therapy), at 6 months, and yearly during a 3-
year follow-up period. 
Results: The DISCOVER program will record patient, healthcare provider, and healthcare 
system characteristics, treatment patterns, and factors influencing changes in therapy. In 
addition, disease control (e.g. achievement of glycated hemoglobin target), management of 
associated risk factors (e.g. hypercholesterolemia and hypertension), and healthcare resource 
utilization will be recorded. Microvascular and macrovascular complications, incidence of 
hypoglycemic events, and patient-reported outcomes will also be captured. 
Conclusions: The DISCOVER program will provide insights into the current management of 
patients with type 2 diabetes worldwide, which will contribute to informing future clinical 
guidelines and improving patient care. 
ClinicalTrials.gov identifiers: NCT02322762 (DISCOVER) and NCT02226822 (J-
DISCOVER). 
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1. Introduction 
In 2015, an estimated 415 million people had diabetes and this number is predicted to 
increase to 642 million by 2040 (International Diabetes Federaion [IDF], 2015), with type 2 
diabetes accounting for the vast majority of cases; studies in high-income countries have 
estimated that 87–91% of all people with diabetes have type 2 diabetes (Boyle et al., 1999; 
Bruno et al., 2005; Evans et al., 2000; Holman et al., 2015). Diabetes and its complications 
are major causes of early deaths in many countries; an estimated 5 million people worldwide 
aged 20–79 years died from diabetes in 2015 (IDF, 2015). Type 2 diabetes is a significant 
risk factor for cardiovascular disease (CVD), which is the most common cause of death in 
people with type 2 diabetes (Morrish et al., 2001). This high risk of CVD is explained in part 
by the high prevalence of other modifiable cardiovascular risk factors in people with type 2 
diabetes, including hypertension, obesity, and dyslipidemia (Preis et al., 2009). The 
management of patients with type 2 diabetes is therefore complex and requires that issues in 
addition to glycemic control be addressed. The need for an individualized and patient-
centered approach to diabetes care is acknowledged by current clinical guidelines, which 
recommend multifactorial management based on the patient characteristics (e.g. age, duration 
of diabetes, life expectancy, presence of comorbidities, and risk of hypoglycemia) (Chinese 
Diabetes Society [CDS], 2014; Garber et al., 2015; IDF, 2012; Inzucchi et al., 2015; Qaseem 
et al., 2012). Thus, physicians are faced with complex decision-making situations in 
optimizing the treatment of their patients with type 2 diabetes. For example, the importance 
of achieving glycemic control to reduce the risk of microvascular and macrovascular 
complications in patients with type 2 diabetes is well established (Holman et al., 2008; Patel 
et al., 2008; Ray et al., 2009; Stratton et al., 2000; UK Prospective Diabetes Study [UKPDS] 
Group, 1998) and current guidelines generally recommend the use of metformin, in 
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conjunction with lifestyle changes, as the first-line glucose-lowering therapy in patients with 
no contraindications and who can tolerate it (CDS, 2014; Garber et al., 2015; IDF, 2012; 
Inzucchi et al., 2015; Qaseem et al., 2012). When metformin monotherapy fails to control 
glycated hemoglobin (HbA1c) levels, guidelines recommend the timely addition of a second 
glucose-lowering agent such as a sulfonylurea, a thiazolidinedione, acarbose, a dipeptidyl 
peptidase-4 inhibitor, a sodium–glucose-linked transporter type 2 inhibitor, a glucagon-like 
peptide-1 (GLP-1) receptor agonist, or basal insulin. However, most guidelines do not clearly 
state optimal treatment pathways upon initiation of second-line therapy (CDS, 2014; IDF, 
2012; Inzucchi et al., 2015; Qaseem et al., 2012); only the American Association of Clinical 
Endocrinologists and American College of Endocrinology diabetes management algorithm 
suggests a clear treatment hierarchy (Garber et al., 2015). This lack of guidance, combined 
with the availability of numerous glucose-lowering agents, means that a wide range of 
therapies is used in second and subsequent lines in clinical practice. Although recent large 
cardiovascular outcomes trials suggest that some therapies can substantially reduce the risk of 
major cardiovascular events such as cardiovascular death, hospitalization for heart failure, 
myocardial infarction, and stroke (Marso et al., 2016; Zinman et al., 2015), little is known 
about treatment pathways and their associations with outcomes after failure of first-line 
therapy in routine clinical practice. Randomized clinical trials alone cannot inform treatment 
decisions in clinical practice because they are restricted to specific populations based on strict 
inclusion and exclusion criteria; longitudinal data on treatment pathways are therefore 
essential to identify the disease, patient, and physician characteristics that are associated with 
the most effective treatment decisions and optimal outcomes. A better understanding of 
practice variations across and within different countries, and their determinants and 
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associated patient outcomes are also key to improving public health policies and reducing the 
economic burden of type 2 diabetes. 
We hypothesized that there is wide variability in the use of glucose-lowering agents as 
second-line therapy for the treatment of type 2 diabetes, and that these differences are related 
to various factors, including system factors (e.g. type of practice, region of the world, access 
to medications, and copayments), patient characteristics (e.g. medical history, comorbidities, 
and presence of risk factors), and physician specialty. We further hypothesized that the 
differences in prescribing patterns are associated with differences in disease and CVD risk 
factor control and evolution, occurrence of complications (microvascular and macrovascular 
events), quality of life, and use of healthcare resources. 
1.1. Study objectives 
The primary objective of the DISCOVER study program is to describe the disease 
management patterns and clinical evolution in patients with type 2 diabetes who are starting a 
second-line glucose-lowering therapy (defined as adding a glucose-lowering drug or 
switching between therapies) after failure of first-line oral treatment with a monotherapy, 
dual therapy, or triple therapy. 
In addition, the study aims to describe the patient, physician, and healthcare system 
determinants of treatment patterns, and the associations between treatment patterns and a 
broad range of outcomes, including glycemic control, hypoglycemic episodes, incidence of 
complications (e.g. microvascular and macrovascular events), healthcare resource utilization 
(e.g. hospitalizations and emergency department visits), and patient-reported outcomes 
(PROs) (Table 1). 
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2. Materials and methods 
2.1. Design 
The multinational DISCOVER study program comprises two similar, observational, 
longitudinal, prospective studies conducted simultaneously: (1) DISCOVER in 37 countries 
(Algeria, Argentina, Australia, Austria, Bahrain, Brazil, Canada, China, Colombia, Costa 
Rica, Czech Republic, Denmark, Egypt, France, India, Indonesia, Italy, Jordan, Kuwait, 
Lebanon, Malaysia, Mexico, Netherlands, Norway, Oman, Panama, Poland, Russia, Saudi 
Arabia, South Africa, South Korea, Spain, Sweden, Taiwan, Tunisia, Turkey, and United 
Arab Emirates) and (2) J-DISCOVER in Japan (Fig. 1). Countries were selected across 
different continents to obtain a global assessment of the current state of type 2 diabetes 
treatment and to gain specific insights in countries with a high prevalence of diabetes (e.g. 
China, India, Brazil, and countries in the Middle East and Africa) and in regions that have 
never or rarely been studied (e.g. Middle East and Africa). DISCOVER recruited patients 
from December 2014 to June 2016; J-DISCOVER recruited patients from September 2014 to 
December 2015. Patients will be followed up for 3 years from initiation of second-line 
therapy (baseline). Baseline data should be available in the first quarter of 2017. 
This is a non-interventional study; enrolled participants will undergo clinical 
assessments and receive standard medical care as determined by their treating physicians. 
Patients will not receive any investigational treatment or experimental intervention as a 
consequence of their participation in the study. Participation is on a voluntary basis and 
patients are free to withdraw from the study at any time and without prejudice to their 
subsequent treatment. Patients lost to follow-up will not be replaced. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
10 
 
 
The study protocol was approved by the appropriate clinical research ethics committees 
in each participating country and by the relevant institutional review board at each site. The 
protocol complies with the Declaration of Helsinki, the International Conference on 
Harmonisation of Good Clinical Practice, and the local regulations for clinical research 
(ClinicalTrials.gov identifiers: NCT02322762 for DISCOVER; NCT02226822 for 
J-DISCOVER). All participating patients provided signed informed consent.  
2.2. Site and investigator selection 
Characteristics of physicians and practices involved in the management of patients with 
type 2 diabetes were assessed in each participating country by combining data from peer-
reviewed articles, information from reports published by organizations such as the World 
Health Organization, and insights from national coordinating investigators. Proportions of 
different types of physicians (primary care physicians, diabetologists, endocrinologists, 
cardiologists, and other specialists) and practices (primary care centers, specialized diabetes 
centers, and different types of hospitals), as well as the location of practices (urban vs rural 
and geographical distribution within a country), were collated. A list of prospective sites that 
would match these characteristics as much as possible was then established for each country, 
and all sites were invited to participate in the study. The number of sites in each country was 
commensurate with the targeted number of patients and the recruitment potential of the sites. 
Practical and logistical reasons (e.g. low recruitment potential or site refusal to participate) 
that may preclude achieving optimal representativeness were documented and will be 
reported and taken into account in the data analysis and/or the interpretation of results. 
Characteristics of the 815 participating sites are shown in Supplementary Table 2. The large 
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majority of sites are primary care centers (53.6%), located in urban areas (74.2%), and 
privately funded (58.3%).” 
2.3. Study participants 
Eligible patients with type 2 diabetes initiating a second-line glucose-lowering 
treatment (add-on or switching) after a first-line oral treatment with a monotherapy, dual 
therapy, or triple therapy were invited to participate in the study by their physician. Patients 
using an injectable agent (i.e. insulin or a GLP-1-receptor agonist) as first-line therapy were 
excluded from the study because they might constitute a population with a more severe 
disease profile, which would warrant a separate study. Patients who received short-term 
initial treatment with insulin followed by oral therapy were eligible if the treatment with 
insulin lasted no more than 2 weeks and occurred at least 6 months before initiation of 
second-line therapy. In such cases, insulin was considered not as a first-line treatment but as 
an acute course to lower glycemic levels quickly before starting regular treatment. All 
inclusion and exclusion criteria are shown in Supplementary Table 1. A total of 16 309 
patients (14 391 in DISCOVER and 1915 in J-DISCOVER; Figure 1) were enrolled. 
2.4. Data collection 
2.4.1. Data collection using an electronic case report form 
For all eligible patients who sign the informed consent form, data will be collected at 
baseline (date of initiation of the second-line therapy) and at 6, 12, 24, and 36 months 
(Fig. 2A). In most countries, data for all time points will be collected by investigators using 
an electronic case report form (eCRF) via a web-based data capture system. Data will be 
saved immediately to a central database, and all eCRFs will be checked to ensure that they 
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are completed appropriately. Where technically feasible and allowed by local regulations, the 
information captured in the eCRF will be linked with other sources of health information, 
such as existing electronic medical records (EMRs) and disease registries, to build a 
comprehensive data resource for research. 
Baseline data will be collected at the routine visit, during which the second-line 
glucose-lowering therapy will be prescribed. If this is not possible (e.g. because of time 
constraints), the investigator will arrange for another visit to take place within 2 weeks to 
collect all necessary information. This will include demographic and anthropometric data, 
available laboratory test results, medical history of type 2 diabetes, presence of comorbidities, 
co-medications, level of care, previous glucose-lowering treatment (first-line therapy) and 
reason for change, second-line glucose-lowering drug class, HbA1c target, and PROs (Table 
2). 
During the 3-year follow-up, data will be captured at 6, 12, 24, and 36 months within a 
4-month window ( 2 months) (Fig. 2A) to increase the probability that the data collection 
time point coincides with a routine patient visit; the protocol does not mandate any 
compulsory follow-up visits in order to ensure that the study results reflect routine clinical 
practice as much as possible. Variables to be recorded will include physiological parameters, 
laboratory test results, change(s) in glucose-lowering therapy and reason(s) for change(s) 
(e.g. suboptimal glycemic control and adverse events), HbA1c level at time of change(s), 
occurrence of microvascular and macrovascular events, occurrence of minor and major 
hypoglycemic events, changes in comorbidities and co-medications, PROs, and healthcare 
resource utilization. In addition, information related to hospitalizations or emergency 
department visits during follow-up (including reason for and duration of hospitalization, 
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details about the ward where the patient was treated, and interventions received) will be 
recorded in specific fields of the eCRF (Table 2). The investigators will be asked to contact 
the physician(s) in charge of the patient during hospitalization to obtain the required 
information. Events identified through this procedure will be classified without further 
assessment. 
In all countries except Japan, additional patients could be enrolled retrospectively to 
compensate for short recruitment periods in countries where protocol approval was delayed. 
All eligible patients who initiated their second-line glucose-lowering therapy between 
December 31, 2014 and the end of the recruitment period in each country could be invited to 
participate in the study and enroll after providing informed consent. Therefore, for countries 
in which recruitment was closed in June 2016, the maximal length of time between initiation 
of second-line therapy and enrollment could be 18 months. For these patients, data from the 
baseline visit and subsequent visits that occurred in the past were collected retrospectively by 
the investigators from medical records (Fig. 2B); PRO questionnaires were not completed for 
these time points. 
2.4.2. Patient-reported outcomes 
PROs will be collected using up to four self-administered questionnaires depending on 
availability in local languages: (1) the 36-item Short-form Health Survey version 2 (SF-36v2) 
will be used to measure general health status across eight domains: vitality, physical 
functioning, bodily pain, general health perceptions, physical role functioning, emotional role 
functioning, social role functioning, and mental health (Ware et al., 2007); (2) the revised 
Hypoglycemia Fear Survey (HFS-II), a 33-item survey using five-point Likert scales (score 
range: 0–132), will be used to assess behaviors and worries relating to fear of hypoglycemia 
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(Stargardt et al., 2009); (3) a seven-item questionnaire will be used to assess patients’ 
lifestyles as ‘unhealthy’, ‘intermediate’, ‘healthy’, or ‘very healthy’, based on questions 
relating to smoking, alcohol intake, physical activity, and diet (Carlsson et al., 2013); and (4) 
a two-item questionnaire will be used to determine whether patients avoided healthcare 
and/or medication because of cost. In addition to the SF-36v2 questionnaire, the 
J-DISCOVER study will use slightly different questionnaires: (1) the Japanese version of the 
diabetes treatment satisfaction questionnaire (DTSQ), an 8-item survey using 7-point Likert 
scales, will be used to assess treatment satisfaction and measure the perceived frequency of 
hyperglycemia and hypoglycemia (Ishi et al., 2000); (2) the brief self-administered diet-
history questionnaire (BDHQ) will be used to assess dietary habits (Kobayashi et al., 2011; 
Sasaki et al., 1998); and (3) the short version of the International Physical Activity 
Questionnaire (IPAQ-SV), a 9-item survey, will be used to estimate physical activity levels 
(Craig et al., 2003; Murase et al., 2002). 
2.4.3. Data collection from electronic medical records 
In Denmark, France, Norway, and Sweden, available study variables will be extracted 
automatically from existing primary care EMR databases. For all patients meeting the 
inclusion criteria at each participating site, EMR data will be extracted at baseline and yearly 
thereafter. At the time of de-identified EMR data extraction, a key code will be created that 
links each patient identification number to their registry data. This key code will be 
encrypted, password protected, and stored separately from the database used for analysis. 
Data not routinely captured in EMR databases (e.g. reason for treatment change) will be 
collected by investigators using an additional questionnaire. These data will then be linked 
back to the EMR to create a full dataset for each patient. In addition, in Denmark, Sweden, 
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and Norway, data extracted from EMRs will be merged with data from mandatory national 
health registries (e.g. information on hospitalizations, prescribed drugs, and cause of death) to 
create a de-identified study database. 
A similar approach will be used in Canada. All patients were identified retrospectively, 
using the IMS Brogan EMR database. Eligible patients were invited to participate and 
enrolled after providing informed consent. Most data will be extracted from the EMR 
database for all time points. A short eCRF completed by the patient will also be used to 
collect additional data not routinely captured in the EMR database (e.g. hypoglycemic events 
and PROs). The eCRF was not be used at baseline because patients were enrolled 
retrospectively. This approach will provide a more limited dataset than in other DISCOVER 
countries; therefore, data from Canada will only be included in the global analysis of the 
DISCOVER results when appropriate. 
In Canada, Denmark, France, Norway, and Sweden, it will also be possible to collect 
EMR data beyond the 3-year follow-up period, providing insights on longer-term disease 
management and outcomes. In these five countries, retrospective data will be collected from 
EMRs and/or national health registries for all patients with type 2 diabetes treated at each 
primary care site participating in the DISCOVER study (including patients not enrolled in the 
prospective DISCOVER study) and analyzed separately. This approach will enable a longer 
observation period in a large cohort and provide important data to assess the external validity 
of the results from the global DISCOVER study. The possibility of implementing a similar 
extended follow-up in other DISCOVER countries will be explored. 
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2.4.4. Adverse event reporting 
DISCOVER is a non-interventional study program and there is no requirement to report 
adverse events. Adverse drug reactions observed in patients participating in DISCOVER will 
be reported to health authorities as required by local regulations and/or if the investigator 
considers reporting to be appropriate. 
2.5. Statistical analysis 
Descriptive statistics will be used to summarize demographic variables, patient 
characteristics, treatment patterns, changes in HbA1c level, blood glucose, lipid profile, body 
weight, body mass index, and blood pressure, incidence of complications and hypoglycemic 
events, PROs, and healthcare resource utilization. Data will be stratified by pharmacological 
drug class and/or individual agent when clinically relevant. Hierarchical multivariate 
regression analyses and general linear models will be used to determine potential predictors 
of treatment choices and clinical outcomes. When applicable, model-based point estimates of 
odds ratios or risk ratios, as appropriate, corresponding 95% confidence intervals, and 
p values will be reported. For analyses of clinical outcomes during follow-up, Cox models 
and mixed models for longitudinal data will be used, adjusted for age and sex, and using 
country as the indicator variable. Time-to-event analyses will be used to describe treatment 
patterns (e.g. initiation of third-line therapy).  
The minimum sample size was estimated to be 11 100 patients, based on the following 
criteria: (1) the intention to have a minimum of 200 patients in any given group of patients to 
be analyzed (e.g. patients receiving a certain drug class or patients from one country), which 
would result in a precision of at least 7% for any expected qualitative variable at a frequency 
of 5–95%; (2) at least 200 patients meeting each of the composite endpoints of macrovascular 
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complications (cardiovascular death, myocardial infarction, ischemic stroke, hospitalization 
for heart failure, coronary revascularization) and microvascular complications (neuropathy, 
retinopathy, nephropathy) at years 1, 2, and 3, based on expected yearly rates for these events 
(5.5% for the composite of macrovascular complications; 10.4% for the composite of 
microvascular complications); (3) at least 200 patients meeting each individual 
macrovascular and microvascular endpoint at year 3 (expected rates over 3 years: 2.4–4.6% 
for macrovascular complications; 3.5–15.7% for microvascular complications); and (4) an 
estimated attrition rate of 15% per year of follow-up.  
All statistical analyses will be performed using the SAS statistical software system 
(SAS Institute, Inc., Cary, NC). 
2.6. Funding and responsibilities 
DISCOVER is funded by AstraZeneca. As it is a non-interventional study, no drugs are 
supplied or funded. The DISCOVER Scientific Committee comprises 12 scientists (L.J., F.B., 
B.C., M.B.G., M.K., K.K., A.N., S.P., W.R., M.V.S., I.S., and H.W.) and the following 
AstraZeneca members: the Scientific Project Leader (J.M.), the Global Medical Affairs 
Leader Diabetes (P.F.), the Global Medical Affairs Medical Evidence and Observational 
Research Diabetes Lead (N.H.), the Medical Affairs Senior Director Japan (K.H.), and former 
International Region Medical Directors (F.S. and G.M.). 
3. Discussion 
Although large, international, non-interventional studies of patients with type 2 diabetes 
have been conducted (Bradley et al., 2011; Echtay et al., 2013; Freemantle et al., 2012; 
Khunti et al., 2012; Kim et al., 2012; Li et al., 2011; Liebl et al., 2012; Mathieu et al., 2013; 
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Matthaei et al., 2012; Oguz et al., 2013; Rosales et al., 2015; Shah et al., 2010; Tsai et al., 
2011; Valensi et al., 2008), they only examined patients treated with insulin (Echtay et al., 
2013; Freemantle et al., 2012; Khunti et al., 2012; Liebl et al., 2012; Matthaei et al., 2012; 
Oguz et al., 2013; Shah et al., 2010; Tsai et al., 2011; Valensi et al., 2008) or another specific 
glucose-lowering drug class (Kim et al., 2012; Li et al., 2011; Mathieu et al., 2013; Matthaei 
et al., 2012; Rosales et al., 2015), were limited to five or fewer countries (Echtay et al., 2013; 
Liebl et al., 2012; Oguz et al., 2013) or included a relatively small number of patients 
(< 1000) (Oguz et al., 2013), were of short duration (follow-up ≤ 6 months) (Echtay et al., 
2013; Khunti et al., 2012; Kim et al., 2012; Li et al., 2011; Rosales et al., 2015; Shah et al., 
2010; Tsai et al., 2011; Valensi et al., 2008), or were cross-sectional (Bradley et al., 2011). In 
addition, many of these studies focused on drug safety and/or efficacy (Echtay et al., 2013; 
Kim et al., 2012; Khunti et al., 2012; Li et al., 2011; Mathieu et al., 2013; Rosales et al., 
2015; Shah et al., 2010; Tsai et al., 2011) and few assessed quality of life (Bradley et al., 
2011; Shah et al., 2010; Valensi et al., 2008), incidence of hypoglycemic events (Echtay et 
al., 2013; Khunti et al., 2012; Valensi et al., 2008), or treatment patterns (Freemantle et al., 
2012; Khunti et al., 2012; Liebl et al., 2012; Matthaei et al., 2012; Oguz et al., 2013; 
Vichayanrat et al., 2013).  
DISCOVER is a global, prospective, observational study of patients with type 2 
diabetes, and it will be the first to report treatment patterns after initiation of second-line 
therapy regardless of the agent(s) prescribed, in a large, contemporary, diverse, and 
heterogeneous population. The study will provide a comprehensive overview of current 
clinical practices in the treatment of patients with type 2 diabetes after failure of first-line oral 
therapy across 38 countries, and will identify potential differences between practice and 
clinical recommendations. The study is designed to generate sufficient data to analyze 
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determinants of treatment decisions, and associations between treatment patterns and several 
disease-specific outcomes, including glycemic control, microvascular and macrovascular 
events, hypoglycemic episodes, and PROs. In addition, the large sample size will allow 
subanalyses to help to identify patient profiles or subgroups that respond well to specific 
therapeutic approaches. Importantly, the DISCOVER study program will generate real-world 
data on the management of type 2 diabetes and associated outcomes in countries with 
alarmingly high and rising prevalences of type 2 diabetes that have been under-studied to 
date. 
DISCOVER is primarily a descriptive study, and representativeness of participating 
patients and physicians is key to meeting the study objectives and ensuring external validity 
of the results. Physicians invited to participate were therefore carefully selected across 
different specialties, care settings, and geographic regions in order to ensure that the findings 
would be representative of the management of patients with type 2 diabetes in each country. 
Nevertheless, physician selection bias should be considered when interpreting the results. 
Physicians who are more involved and/or competent in the treatment and management of 
diabetes may be more likely to participate and to treat patients earlier. In this case, the results 
of DISCOVER may slightly overestimate disease control and quality of care in day-to-day 
clinical practice. However, the large number of participating investigators (> 1000) across all 
specialties and from different clinical settings, and the inclusion of a diverse patient 
population, are likely to provide an accurate overview of diabetes management in each 
participating country or region. 
DISCOVER uses PRO questionnaires and therefore relies on patients’ recollection to 
determine the incidence of some events (e.g. minor hypoglycemic events); recall bias may 
therefore also influence the results of the study. However, this potential misclassification of 
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outcomes is unlikely to be systematically associated with patient characteristics, risk of 
complications, or exposure to glucose-lowering agents. In addition, results from these 
questionnaires should be interpreted cautiously in light of data missing from patients enrolled 
retrospectively. Loss to follow-up might also be a source of bias. Patients with poorly 
controlled diabetes may be more likely to drop out over the 3-year follow-up than those with 
better outcomes, which could result in an underestimation of negative outcomes. It should 
also be noted that patient visits are not determined by the protocol; therefore, data collection 
during follow-up will rely on patients attending regular routine visits (the frequency of which 
may be country dependent) and on investigators being able to collect all relevant information 
(e.g. data about hospitalizations or emergency department visits). Finally, in common with all 
observational studies, confounding should be considered when interpreting the results. 
However, the available variables collected using the study eCRF will be used in multivariate 
analyses to minimize confounding when assessing associations between clinical outcomes 
and patient, physician, and healthcare system characteristics, and treatment patterns.  
The DISCOVER study program also has major strengths in addition to the large sample 
size and the broad geographical representation. First, the naturalistic design of the studies, 
whereby the chances of protocol-induced findings and protocol-induced healthcare resource 
use are minimized, will help to ensure external validity of the results. In addition, the same 
eCRF will be used in all countries, ensuring consistent data collection. This user-friendly 
eCRF, combined with a relatively small target number of patients (< 20 on average) per 
investigator, will ensure that the time burden for investigators is minimal and that data are 
collected completely and accurately for all patients. The long follow-up period is also a key 
strength of DISCOVER and will allow the study of treatment patterns beyond initiation of 
second-line therapy. In some countries, prospective data collection will be complemented by 
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data extracted from existing EMR databases, thus providing the opportunity to follow up 
some patients for longer than 3 years. Comparison of data extracted from EMRs and data 
collected with the eCRF may also inform the design of future observational studies. In 
addition, the DISCOVER study program will allow platforms for future research to be set up 
in countries with no previous systems for the capture of observational data from patients with 
type 2 diabetes. 
It should be noted that, although the DISCOVER study program does not cover the 
USA, it has been developed in parallel with the recently launched Diabetes Collaborative 
Registry (DCR) (Arnold et al., 2016), which has the potential to become the largest cross-
specialty clinical registry to track, evaluate, and eventually improve the quality of diabetes 
and metabolic care in the USA. The DCR captures similar data via EMR data extraction and 
will complement the DISCOVER results from 38 other countries. Studies of this type are 
essential to review trends in prescribing practices, diabetes management, and clinical 
outcomes, in order to help improve the standard of care for patients with type 2 diabetes. 
4. Conclusion 
The DISCOVER study program is a global initiative that will provide valuable insights 
into the treatment of patients with type 2 diabetes in real-world settings and will highlight 
differences between daily clinical practice and recommendations in current national and 
international guidelines. In addition, collection of patient-centric health status and healthcare 
resource utilization data will enable the evaluation of important outcomes beyond glycemic 
control and clinical events. The DISCOVER study program will also allow benchmarking of 
clinical practice between and within countries, help to inform future updates to clinical 
guidelines, and will further improve the care of patients with type 2 diabetes. 
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Figure legends 
Fig. 1. Countries participating in the DISCOVER study program (indicated in dark gray), and 
number of enrolled patients in each country. 
 
Fig. 2. Study timelines. A. Patients enrolled on the day of initiation of second-line glucose-
lowering therapy. B. Patients enrolled retrospectively (after initiation of second-line glucose-
lowering therapy). 
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Fig. 2 
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Table 1 
Study objectives. 
Primary objective 
 To describe the disease clinical course and management patterns in patients with type 
2 diabetes initiating a second-line glucose-lowering therapy (defined as adding a 
glucose-lowering drug or switching between therapies), after a first-line oral 
treatment with a monotherapy, dual therapy, or triple therapy 
Secondary objectives 
 To describe treatment response overall, by patient characteristics, and by second-line 
glucose-lowering medication class as assessed by: 
o changes in HbA1c levels 
o changes in body weight 
o changes in blood pressure 
o changes in lipid profile 
o achievement of HbA1c targets  
 To describe treatment changes after initiation of second-line therapy, including: 
o addition of other glucose-lowering medications 
o initiation of insulin therapy 
o switching between glucose-lowering therapies 
o dose changes 
 To determine the incidence of microvascular complications: 
o diabetic nephropathy 
o diabetic neuropathy 
o diabetic retinopathy 
o diabetes-related non-traumatic amputation 
 To determine the incidence of macrovascular complications: 
o cardiovascular death 
o heart failure 
o myocardial infarction 
o stroke 
o diabetes-related revascularization 
 To assess patient-reported outcomes: 
o general health status (using the SF-36v2) 
o fear of hypoglycemic events (using the Hypoglycemia Fear Survey) 
o general health status (based on smoking, diet, physical activity, and alcohol 
intake) 
o whether patients avoided healthcare and/or medication because of cost 
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 To describe healthcare resource utilization 
 To determine risk factors associated with microvascular and macrovascular 
complications, hypoglycemic events, loss of quality of life, and increased healthcare 
resource utilization during follow-up: 
o patient characteristics (e.g. age, sex, comorbidities, and socioeconomic status) 
o disease characteristics (e.g. duration of diabetes) 
o treatment characteristics (e.g. second-line glucose-lowering medication class) 
o physician/practice characteristics (e.g. primary care vs specialists) 
 To describe factors associated with treatment choice at baseline 
HbA1c: glycated hemoglobin, SF-36v2: 36-item Short-form Health Survey version 2.  
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
38 
 
 
Table 2 
Data collection at baseline (initiation of second-line therapy) and 6, 12, 24, and 36 months. 
 
Baseline 
data 
collection 
Follow-up 
data 
collection 
a 
Site and investigator characteristics 
 Center type (primary care, university hospital, general 
hospital, specialized diabetes center) 
 Geographical setting (urban, rural) 
 Center funding (public, private, mixed) 
 Physician specialty (PCP, endocrinologist, cardiologist, 
internist, other specialist) 
  – 
Informed consent form   – 
History of diabetes 
 Date of diagnosis 
 Treatment (class of drug, duration, dose) 
 Evidence of microvascular complications (nephropathy, 
retinopathy, neuropathy, amputation) 
 Diabetes education received by patient  
 Risk factors (alcohol use, smoking status) 
  – 
First-line glucose-lowering drug and reason for change   – 
Initiation of second-line glucose-lowering treatment 
 First-line glucose-lowering drug class (specific agent if data 
are available) 
 Second-line glucose-lowering drug class (specific agent if 
data are available) 
 HbA1c target 
 Reason for initiating second-line therapy 
 Reason for choice of second-line therapy 
  – 
Demographics  
 Sex 
 Date of birth 
 Self-reported ethnic origin 
 Living status (living alone, not living alone) 
 Education level (basic, low, medium, high) 
 Employment status (employed, unemployed) 
   
Comorbidities    
Co-medications    
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Baseline 
data 
collection 
Follow-up 
data 
collection 
a 
Physiological and anthropometric parameters 
 Seated blood pressure 
 Pulse rate 
 Weight 
 Height 
 Body mass index 
 Waist circumference 
   
Laboratory test results (most recent results available for the past 
3 months) 
 Blood test results (HbA1c and/or glucose level [fasting, 
post-prandial or casual], aspartate aminotransferase, alanine 
aminotransferase, γ-glutamyl transpeptidase, creatinine, 
albumin, hematocrit, hemoglobin, total cholesterol, LDL-C, 
HDL-C, and triglycerides levels, white blood cell and 
platelet counts) 
 Urine test results (protein, albumin, creatinine) 
   
Healthcare resource utilization  
 Number of visits to PCP, specialist, and emergency 
department 
 Hospitalizations 
o Number and duration (by ward) 
o Reason (diabetes-related or not, and specific 
diagnosis) 
o Test and procedures 
 Tests and procedures not requiring hospitalization 
 Severe hypoglycemic events requiring medical assistance 
 Medications 
 Glucose-monitoring equipment 
 Educational resources 
 Number of days off work because of illness 
–  
Patient-reported outcome questionnaires b
 
 SF-36v2 
 HFS-II 
 Lifestyle score 
 Healthcare avoidance due to cost 
   
Occurrence of minor hypoglycemic event(s) (past month)    
Occurrence of major hypoglycemic event(s) (past year at baseline    
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Baseline 
data 
collection 
Follow-up 
data 
collection 
a 
and since last visit during follow-up) 
Occurrence of microvascular and macrovascular complication(s) –  
Change(s) in glucose-lowering treatment and reason(s) for 
change(s)  
–  
a
 Follow-up visits at 6, 12, 24, and 36 months within a 4-month window ( 2 months). 
b
 Patient-reported outcomes will not be collected for baseline and for any data collection time 
point occurring before enrollment for patients identified retrospectively. Patients will only 
complete questionnaires available in their country. 
HbA1c: glycated hemoglobin, HDL-C: high-density lipoprotein cholesterol, HFS-II: revised 
Hypoglycemia Fear Survey, LDL-C: low-density lipoprotein cholesterol, PCP: primary care 
practitioner, SF-36v2: 36-Item Short-Form Health Survey version 2. 
